Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Shares of 3SBio jumped as much as 52% in Hong Kong, the most on record, extending gains for the third consecutive session.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

CEOs are yet to collectively, and definitively, stand up to President Donald Trump's attacks against businesses.

Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...